The immortalized murine stromal cell line AFT024 has been reported to maintain human hematopoietic progenitors in an undifferentiated state in vitro. In the current studies the beige/nude/xid (bnx) mouse in vivo xenograft model was used to examine the engraftment and multilineage generative potential of human hematopoietic progenitors after 2-3 weeks growth on AFT024 stroma, in comparison to primary stromal monolayers derived from post-natal human bone marrow. Eight to 12 months after transplantation of human CD34 +
Introduction
The proliferation, differentiation and maintenance of hematopoietic progenitors in vivo are dependent on the microenvironment produced by stromal cells. A stromal cell line derived from murine fetal liver (AFT024) has been shown to maintain long-term repopulating murine stem cells for up to 7 weeks in vitro. 1 We recently reported that AFT024 stromal cells also support the maintenance of the primitive function and immunophenotype of human CD34 +
CD38
− progenitors in vitro. 2 Verfaillie's group has reported that the AFT024 cell line maintains primitive human hematopoietic cells in culture, through novel 'non-contact' systems. [3] [4] [5] [6] [7] [8] However, there have been no reports, to date, examining whether the AFT024 cell line maintains the multilineage engraftment capacity of human hematopoietic stem and progenitor cells, and this was the objective of the current study.
Human hematopoietic cells that express the cell surface antigen CD34, but lack expression of the differentiation-associated antigen, CD38, are one of the most primitive populations of stem/progenitor cells that has been identified to date. [9] [10] [11] [12] [13] [14] [15] [16] We used this cell population, isolated from normal human umbilical cord blood, to examine the effects of AFT024 stroma during 2-3 weeks in vitro culture, in the current studies. The cells cultured on the AFT024 stromal cell monolayers were directly compared to the same starting cells, cultured for the same duration, in the same medium, but on primary stromal monolayers derived from post-natal human bone marrow (human stroma: HS). Following the 2 or 3 week culture period, the cells from the AFT and HS groups were transplanted into immune deficient beige/nude/xid (bnx) mice to assess long-term engraftment levels. The bnx mouse lacks its own T cells, B cells and natural killer (NK) cells and thus is a suitable model for studying human hematopoiesis in vivo. Human myeloid cells, erythroid progenitors, B lymphocytes and extrathymically derived T lymphocytes develop in bnx mice following transplantation of purified stem cells. [17] [18] [19] [20] [21] The lifespan of the bnx mouse is longer than that of the commonly used NOD/SCID strain, since the bnx does not carry the emv-30 provirus, which causes lethal thymoma in NOD/SCID mice. 22 The bnx mouse was therefore chosen as the xenogeneic host for the cultured human hematopoietic cells in the current studies, so that multilineage long-term engraftment could be examined. The mice were killed and analyzed 8-12 months after transplantation. We found that human hematopoietic stem cells that could home into the murine bone marrow and give rise to all lineages of human hematopoietic cells were maintained at significantly higher levels on AFT024, as compared to normal human stroma.
We have recently described that expression of CD34 is reversible on human hematopoietic stem cells that maintain the capacity for regeneration (Refs 23 and 42, and Dao, Arevalo and Nolta, manuscript in preparation). Human CD34
++

/CD38
− cells that are allowed to undergo long-term engraftment (7-18 months) in bnx mice lost expression of CD34, as they became deeply quiescent. The CD45
/Lineage
− cells recovered from the bone marrow of the mice after long-term engraftment retain the capacity for generation of colony-forming units, long-term culture initiating cells (LTCIC), and can give rise to multilineage engraftment with upregulation of CD34 in secondary immunedeficient mouse recipients (Refs 23 and 42, and Dao, Arevalo and Nolta, manuscript in preparation). In the current studies, we have determined that the primitive CD45 
/CD38
− cells, were present at significantly higher levels in bnx mice transplanted with cells that had been cultured for 2 or 3 weeks on the cell line AFT024, as opposed to human stroma. The data in the current report 353 demonstrate that the AFT024 stromal cell line has unique properties that improve maintenance of the capacity of primitive human hematopoietic stem cells to generate long-term, multilineage engraftment.
Materials and methods
Cell sources
Umbilical cord blood was obtained after vaginal and cesarean deliveries at Kaiser Permanente Hospital Sunset (Los Angeles, CA, USA) by drainage of blood into sterile collection tubes containing the anticoagulant citrate-phosphate-dextrose (Sigma, St Louis, MO, USA). All cord blood specimens were obtained according to guidelines approved by the Childrens Hospital Los Angeles Committee on Clinical Investigation. Cells were processed within 24 h of collection.
Isolation of CD34
+ CD38 − cells by fluorescence activated cell sorting Mononuclear cells were isolated from cord blood using Ficoll-Hypaque (Pharmacia, Piscataway, NJ, USA) density centrifugation. The cells were washed with HBSS (BioWhittaker, Walkersville, MD, USA) and residual red blood cells were lysed with Ortho Lysis Buffer (Ortho Diagnostic Systems, Raritan, NJ, USA). The mononuclear fraction was enriched for CD34
+ cells using the mini-Magnetic Activated Cell Sorter system (mini-MACS from Miltenyi Biotec, Auburn, CA, USA), which provides an 85-90% pure CD34
+ population. The cells were then resuspended in cold phosphate-buffered solution (PBS; Irvine Scientific, Santa Ana, CA, USA) at a concentration of 1 × 10 6 per 100 l and incubated with 20 l undiluted FITC-labeled anti-CD34 (HPCA2-FITC; Becton Dickinson (BD), San Jose, CA, USA) and PE-labeled anti-CD38 (Leu 17-PE; BD) per 1 × 10 6 cells. Cells used for isotype controls were incubated with 50 l of FITC-murine IgG (diluted 1:100; Coulter, Hialeah, FL, USA) and 50 l of PE-murine IgG (diluted 1:50; Coulter). All incubations were carried out at 4°C. After incubation with the designated combination of directly conjugated antibodies, the cells were washed once in PBS and isolated by FACS. All cell analysis and sorting was performed on a FACSVantage (BD) equipped with an argon laser tuned to 488 nm, as previously described.
14 For cell isolation purposes, CD34 +
CD38
− cells were defined strictly as those within the 'lymphoid region' with high CD34 antigen expression and CD38 fluorescence less than half of the maximum PE fluorescence of the isotype control. CD34
− cells were transplanted into immune deficient mice 24 h after isolation or after 2 vs 3 weeks of culture on AFT024 vs normal human stromal monolayers, as described below.
Pre-transplantation in vitro cultures
Primary human stromal cells were isolated from the screens used to filter marrow during harvest of allogeneic bone marrow donors. Screens were flushed in the Operating Room at CHLA (under approval by the Committee on Clinical Investigation), then spicules from the bone marrow were collected by gravity sedimentation and plated in Dexter's original medium (DOM = 350 ml Iscove's modified Dulbecco's medium (IMDM), 75 ml screened heat-inactivated (HI) horse Leukemia serum, 75 ml screened HI fetal calf serum (Omega Scientific, Tarzana, CA, USA), 5 ml l-glutamine (200 mm stock; Gibco/BRL), 2.5 ml Pen/Strep (stock = 10 000 U/ml penicillin and 10 000 g/ml streptomycin; Gibco/BRL), 500 l 2-ME (10 −1 m stock; Sigma), 500 l hydrocortisone (10 −3 m stock; Sigma)). The stromal cells were allowed to adhere to the flasks overnight, then the non-adherent cells were removed and the stromal monolayer was allowed to expand, resulting in a relatively homogeneous monolayer of myofibroblastic cells that have less than 1% contaminating CD45
+ macrophages, when analyzed by FACS, by passage three. The murine stromal cell line AFT024 was derived from day 14 fetal liver by immortalization with a retroviral vector encoding a temperaturesensitive SV40 large T antigen.
1 AFT024 was cultivated in 10% FCS in Dulbecco's modified Eagle's medium with 4500 mg/l Glucose (DMEM High Glucose; Irvine Scientific, Santa Ana, CA, USA), with 50 m 2-ME, P/S and l-glutamine and grown at 32°C in 5% CO 2 . Sub-confluent layers of primary stromal cells and AFT024 cells were split by trypsinization (trypsin-EDTA; Irvine Scientific). Within 1 week before addition of hematopoietic progenitors, the stromal cultures were trypsinized, irradiated with 20 Gy, and 2 × 10 4 cells per well (for both cell types) were plated in 24-well plates (Corning Costar Corporation, Cambridge, MA, USA) in 'Basal Bone Marrow Medium' (BBMM, which is IMDM with 30% FCS, 1% bovine serum albumin (BSA; Sigma), 100 m 2-ME, 10 −6 mol/l hydrocortisone (Sigma), 50 U/ml penicillin G, 50 g/ml streptomycin sulfate, and 2 mm l-glutamine). CD34
+
CD38
− cells were isolated by FACS as described, 2, 14, 24 and plated at 2000 cells/well on to pre-established, irradiated AFT024 or HS layers, in BBMM containing interleukin (IL)-3 (10 ng/ml), IL-6 (50 U/ml) and Steel factor (SF; 50 ng/ml). Cultures were fed twice a week by replacing 50% of the medium.
Mice
All studies used 6-week old beige/nude/xid homozygous mice (bg.bg/nu.nu/xid.xid, NIH-3, Taconic Farms) bred at CHLA. Co-transplantation of human progenitors and stromal cells producing IL-3 was performed as previously published, 19, 24 with sublethal conditioning of the mice by injection of 150 g/kg 
/CD38
− cells, then cultured on AFT024 or human stroma for 2 or 3 weeks. Mice were killed by 90% CO 2 /10% O 2 narcosis, 8-12 months after transplantation with human cells. Bone marrow was flushed from the tibiae and femurs of each mouse into 1 × phosphate-buffered saline (PBS), dispersed with a fine needle, counted and used for FACS analysis and humanspecific CFU plating as described. 19, 24 
FACS analysis
Single cell suspensions from the marrow of long-term engrafted bnx mice were preincubated for 15 min on ice with unconjugated mouse immunoglobulin (MsIgG; Coulter) prior to addition of antibody. Directly conjugated antibodies used to identify human-specific cell surface antigens were HLE-1 (anti-CD45, BD); My9-RD1 (anti-CD33, Coulter), Leu-12 (anti-CD19, BD), HPCA-2 (anti-CD34, BD), Leu 17 (anti-CD38, BD), My 7 (anti-CD13, Coulter), Leu 16 (anti-CD20, BD), Leu-3a (anti-CD4, BD) and Leu-2a (anti-CD8, BD). The anti-mouse CD45 antibody (Pharmingen, San Diego, CA, USA) was used to identify murine leukocytes. Following a 15 min antibody binding period on ice, cells were depleted of red blood cells by resuspension in Ortho Lysis Buffer (BD), washed, and fixed in 1% paraformaldehyde. Samples were acquired on a Becton Dickinson FACScan and analyzed using the CellQuest software package (BD). Ten thousand events were acquired for each sample. Parallel staining and FACS analyses were done on non-transplanted human and bnx mouse bone marrow controls, to confirm that none of the human-specific antibodies cross-reacted with murine cells.
Human-specific CFU plating
To determine the number of clonogenic human hematopoietic progenitors engrafted within the murine bone marrow, cells harvested from each mouse were plated in human-specific CFU assay as described. 19, 24 Prior to plating, the bnx/hu bone marrow cells were incubated in IMDM with 20% fetal bovine serum (Omega Scientific, Tarzana, CA, USA) for 4-12 h to remove (by adherence) murine stromal cells, which secrete murine cytokines and invalidate the specificity for growth of human hematopoietic colonies measured in the assay. The medium used for CFU plating was IMDM with 30% FCS (Omega Scientific), 1% BSA (Sigma), 1.3% methylcellulose (Sigma), 10 −4 m 2-mercaptoethanol, 50 U/ml penicillin G, 50 g/ml streptomycin sulfate, 2 mm l-glutamine, 10 −6 m hydrocortisone, and 10 ng/ml rHIL-3 (Immunex, Seattle, WA, USA). Recombinant human erythropoietin (Epoietin alpha; Amgen Corp., Thousand Oaks, CA, USA) was added on day 4 of culture to a concentration of 2 U/ml. Methylcellulose, FCS, and BSA were previously screened to provide maximal CFU-GEMM development from human CD34 + cells. 5 × 10 4 and 1 × 10 5 plastic non-adherent cells from engrafted and control mice were plated in duplicate in 1 ml of the medium in gridded culture dishes (Nunc, Naperville, IL, USA). Colonies were enumerated on day 21 as previously described. 19, 24 In this medium, growth of murine colonies was observed only when stromal cells had contaminated the CFU dish. Therefore, any plates containing adherent stromal or fibroblastic colonies were discarded.
Statistical analyses
The significance of each set of values was assessed using the two-tailed t-test assuming equal variance with the Excel 5.0 software (Microsoft Corporation, Seattle, WA, USA). Average values are listed with standard deviations, and the standard error of the mean was used if all values were listed in table format.
Results
Total human hematopoietic cell engraftment in immune deficient mice
In the current studies we examined the capacity for CD34
− cells from human umbilical cord blood to sustain long-term engraftment in immune deficient mouse hosts, 24 h after isolation, or following culture on the AFT024 stromal cell line, in comparison to culture on normal human stromal cells. These studies were designed to determine whether proteins produced by the AFT024 stromal cell line would affect the ex vivo maintenance of human hematopoietic stem/progenitor cells, and whether the AFT024 line would better sustain the long-term engrafting cells from the human CD34
− population through a period of ex vivo culture than would primary human stromal cell monolayers. If the AFT024 line showed better maintenance, then future studies would analyze the effects of individual proteins cloned from that cell line, transduced into the normal human stromal cells (as we have previously described for other cytokine genes), to determine whether the same response could be obtained. In vitro studies had previously suggested that the AFT024 line was superior to normal human stroma for maintenance of primitive cells, but the comparison had not been previously tested for engrafting human stem/progenitor cells with generation of multilineage progeny in vivo following the culture period, which was the goal of the current studies.
Engraftment of freshly isolated human CD34
− cells from umbilical cord blood was tested in an initial series of experiments. The cells were cultured for 24 h in IL-3, IL-6, and SCF prior to transplantation. In the stromal culture comparison experiments, the cells were cultured for 2-3 weeks with the same concentrations of cytokines and serum. A total of nine mice injected with human CD34
− cells cultured for only 24 h prior to transplantation survived to be analyzed 8-12 months later. The percentages of each lineage detected in the murine marrow are discussed below, in comparison to the levels obtained from the cultured cells.
We next compared the ability of the AFT024 line and primary human stromal monolayers to support human hematopoietic stem/progenitor cells through a period of ex vivo culture. CD34
+
CD38
− cells were cultured in identical conditions, but on the AFT024 cell line vs on human stromal cell monolayers, for 2 vs 3 weeks. Following the culture period, the cells were transplanted into immune-deficient bnx mice and allowed to contribute to long-term hematopoiesis. A total of 12 mice that were transplanted with human cells from AFT024 co-cultures survived for long-term analysis (five mice after 2 weeks and seven mice after 3 weeks of culture), and 10 mice transplanted with human cells from HS co-cultures survived for long-term analysis (three mice transplanted after 2 weeks and seven mice after 3 weeks of culture). After 8-12 months, the animals were killed and the bone marrow was harvested to assess the levels of engraftment of human hematopoietic cells.
The mean percentage of human CD45 + cells that were engrafted in the bone marrow of the mice transplanted with the human cells cultured for only 24 h was 14.0 ± 2.4%. In comparison, the engraftment of total human hematopoietic cells was equivalent after co-cultivation on AFT024, but was significantly lower following culture on HS from all samples of cord blood CD34
+ /CD38 − cells tested. After 2 weeks of culture on AFT024, 14.1 ± 2.6% (mean ± s.e.m.) huCD45 + cells were detected in the bnx mouse bone marrow, as compared to 5.72 ± 1.9% after culture on human stroma (Figure 1 ). Engraftment levels from the mice transplanted with cells maintained ex vivo on both types of stroma after 3 weeks of culture were similar to the levels obtained after 2 weeks of culture (14.0 ± 3.1% huCD45 + cells with AFT024 and 4.8 ± 1.3% with HS). The level of total human hematopoietic cell engraftment was significantly higher after 3 weeks of culture on AFT024 than after the same duration of culture on HS (P = 0.009).
Figure 1
Total human hematopoietic cell engraftment. The percentage of human hematopoietic cell engraftment in the bone marrow recovered from each of the mice was determined by labeling and FACS analysis using (a) a human-specific panleukocyte marker, CD45, or (b) an antibody to human CD38. The mean ± s.e.m. is shown for mice transplanted in six independent experiments. The levels of human CD45
+ and CD38
+ cells in mice transplanted with human progenitors cultured on AFT024 were significantly higher than in mice transplanted with cells cultured on human stroma, after either 2 or 3 weeks in culture. The P value was 0.009 for the difference in the CD45 levels generated from cells transplanted after 3 weeks and P = 0.01 for the difference in the CD38 levels generated from cells transplanted after 3 weeks.
The results for engraftment of CD38 + cells, a marker of human hematopoietic cells that are differentiated or have committed to differentiation, were similar to the results for total CD45
+ cells. A mean of 10.1 ± 3.2% huCD38 + cells were detected in the bnx mouse marrow after 2 weeks of culture on AFT024, as compared to 3.7 ±2.5% after 2 weeks of culture on human stroma (Figure 1 ). The levels of human CD38 + cells detected in the marrow of mice transplanted with human cells cultured for 3 weeks prior to transplantation were again similar to the levels obtained in mice transplanted with cells that had been cultured for 2 weeks (11.5 ± 2.7% huCD45 + cells with AFT024 and 4.4 ± 1.2% with HS). The levels of human CD38
+ hematopoietic cell engraftment were significantly higher after 3 weeks of culture on AFT024 than after the same length of culture on HS (P = 0.01).
Human myeloid engraftment
Engraftment of myeloid lineage cells was greater after co-cultivation on AFT024, as compared to HS. After 2 weeks of culture on AFT024, a mean of 7.4 ± 1.0% CD33 + cells and 6.2 ± 1.7% CD13 + cells were found in the murine bone marrow. In mice that had been transplanted with human CD34 +
CD38
− cells cultured on HS for 2 weeks, 2.5 ± 0.6% CD33 + cells and 2.0 ± 1.0% CD13 + cells were identified ( Figure 2 ). After 3 weeks of culture on AFT024, a mean of 9.9 ± 2.6% CD33 + cells and 7.5 ± 2.0% CD13 + cells were found in murine bone marrow. After 3 weeks of culture on HS, 2.9 ± 0.8% CD33 + and 2.7 ± 0.8% CD13 + cells were identified. In comparison, the average percentage of human CD33 + cells recovered from the mice transplanted with the freshly isolated CD34
− cells was 5.8 ± 1.1, a slightly lower value than that obtained from the mice transplanted Leukemia with the cultured cells, but lacking significant difference at the 2-week timepoint. The percentage of CD33 + cells detected in the marrow of the mice transplanted with the 3-week AFT024 cultures was significantly higher than the percentage of CD33 + cells in the marrow of the mice transplanted with the cells that were cultured for only 24 h prior to transplantation (9.9 ± 2.6 vs 5.8 ± 1.1, P Ͻ 0.001). There was no significant difference between the values obtained from the 24 h cultured cells and the cells cultured for 3 weeks on human stroma, however. These data demonstrate that human hematopoietic cells that could give rise to myeloid engraftment in the mice were best maintained through the in vitro culture period on the AFT024 stroma, as opposed to the human stroma (P = 0.012 for CD33
+ cells, and P = 0.017 for CD13 + cells).
Human T lymphoid engraftment
We have previously demonstrated that highly purified human hematopoietic stem cells give rise to T lymphocytes through extrathymic mechanisms in bnx mice. 17, 18, 25, 26 In the current studies, we determined that this phenomenon occurs even when the human hematopoietic stem/progenitor cells were cultured in vitro for up to 3 weeks prior to transplantation into the mice. The average percentage of human CD4
+ and CD8 + cells detected in the marrow of mice transplanted with cells cultured for only 24 h prior to transplantation was 4.0 ± 0.8 and 3.0 ± 0.5, respectively. In the stromal comparison studies, the values were lower than for the minimally cultured cells, but the levels of both CD4 + and CD8 + T lymphoid cells were significantly higher after co-cultivation on AFT024 than on human stroma. After 2 weeks of culture on AFT024, 1.5 ± 0.4% of the murine bone marrow consisted of CD4 + human cells, as compared to 0.5 ± 0.4% CD4 + cells on HS. After 3 weeks of culture on AFT024, 1.5 ± 0.3% CD4 + cells were found in the bnx BM, as compared to 0.6 ± 0.1% CD4 + cells after culture on HS (P = 0.001) (Figure 3) . A mean of 2.2 ± 0.6% CD8 + cells was identified in the bnx bone marrow after 2-week AFT024 transplants, as compared to 0.8 ± 0.5% Figure 3 T lymphoid engraftment. The percentage of human T lymphocytes in the bnx bone marrow were determined by FACS analysis for (a) CD4, and (b) CD8. The mean ± s.e.m. is shown for mice transplanted in six independent experiments. After both 2 and 3 weeks of culture on AFT024, the transplanted cells generated significantly higher numbers of both CD4
+ and CD8 + cells in the bnx marrow, as compared to cells cultured on HS (P = 0.001 for the difference in CD4
+ cells observed after 3 weeks of culture, and P = 0.034 for the difference in CD8
+ cells detected in mice transplanted with cells cultured for 3 weeks).
after 2-week HS transplants. After 3 weeks on AFT024, a mean of 1.5 ± 0.2% CD8 + cells was detected in the bnx marrow, as compared to 0.8 ± 0.2% CD8 + cells after 3 weeks on HS (P = 0.034). These data show that uncultured cells had the highest T lymphopoietic capacity, but that it was maintained to significantly better levels through culture on AFT024, as opposed to human stroma.
Human B lymphoid engraftment
We recently reported that human CD19 + B cells develop in bnx mice transplanted with 2000 human CD34
− cells isolated from umbilical cord blood, but not in mice transplanted with the same number of CD34
− cells isolated from human bone marrow. This difference is likely due to the lower frequency of B cell progenitors present in human bone marrow, as compared to umbilical cord blood. 27 In the current study we demonstrated that the percentage of CD19 + B cells that develop from human cord blood CD34 +
CD38
− cells in bnx mice is higher after being maintained ex vivo on AFT024 than on human stroma. CD19 + cell engraftment averaged 2.3 ± 0.4% in mice that had been transplanted with cells from the 2-week AFT024 cultures, and 1.0 ± 0.2% in the group transplanted with cells from 2-week HS cultures (Figure 4 ). In contrast, the average percentage of human CD19
+ cells recovered from the marrow of mice transplanted with cells cultured for only 24 h was 1.5 ± 0.3%, a value that did not differ significantly from either value from the 2-week cultures. At least 95% of the human CD19
+ cells that were found in the bnx marrow co-expressed CD20 (data not shown), indicating that they were relatively mature human B cells. Engraftment levels fell significantly after 3 weeks of culture on both types of stroma. An average of 0.9 ± 0.2% human CD19
+ cells were detected in the marrow of mice transplanted with cells from the 3-week AFT024 cultures, as compared to 0.5 ± 0.2% from the 3-week HS cultures. Due to the low percentages of human B cells in the mice following 3 weeks of culture, there was no significant difference between the two culture conditions. This was the only lineage observed in which the AFT024 Figure 4 B lymphoid engraftment. Human CD19 + cells engrafted in bnx bone marrow. The percentages of B lymphoid cells in the bnx bone marrow at the time of harvest were determined using an antibody to the B cell marker CD19. The mean ± s.e.m. is shown for mice transplanted in six independent experiments. Unlike the results for the other lineages tested, there was no significant difference in the numbers of human CD19
+ cells detected in mice transplanted with human cells cultured on AFT024, as opposed to human stroma, after 2 or 3 weeks of culture.
Leukemia stroma did not maintain significantly higher numbers of progenitors throughout the 3-week culture period.
Primitive human hematopoietic cell engraftment
Consistent with our previous studies using the bnx/hu system, although a purified population of CD34
− cells were used to initiate the stromal co-cultures prior to transplantation (Figure 5a ), CD34
+ cells were not detectable in any of the mice at the time of harvest and analysis (Figure 5b ). However, we have recently determined that expression of CD34 is lost in human progenitors that have engrafted long-term in bnx mice. We have identified a CD45 + /lineage − human hematopoietic cell that lacks expression of CD34, but is capable of colony formation, long-term culture initiation, and multilineage reconstitution (Refs 23 and 42, and Dao, Arevalo and Nolta, manuscript in preparation). In the current study, the percentages of cells with the CD45
− phenotype were significantly higher in mice that had been transplanted with cells that had been cultured on AFT024 stroma than on human stroma (7.0 ± 1.8% vs 2.1 ± 1.4%, respectively, P Ͻ 0.05). Figure 5c shows the relative percentages of the total CD45 Another primitive human hematopoietic cell phenotype that has been recently described is the CD34 − CD38 − lin − cell. 28, 29 In the current studies, we detected a significant population of human CD45 + cells that lacked expression of both CD34 and CD38, as well as other lineage markers, in the bone marrow of the mice. This population of cells was recovered in significant levels from all sets of mice except for those transplanted with the human cells cultured on normal human stroma for 3 weeks (Figure 5c ). The CD45
− population includes cells that lack lineage commitment, and this population was detected at significantly higher levels in mice transplanted with cells cultured for 2 and 3 weeks on AFT024, as compared to human stroma. An average of 3.7 ± 0.3% engraftment of CD45
− cells was recovered in the bone marrow of mice that had been transplanted with human cells cultured on AFT024 stroma prior to transplantation, as compared to 1.2 ± 0.5% with cells cultured on human stroma (P Ͻ 0.05). Figure 5c shows the relative percentages of the total CD45 + graft that were composed of CD34 To support the phenotypic data, and to further confirm that there were higher numbers of primitive human hematopoietic cells engrafted in the marrow of mice that had been transplanted with the stem/progenitor cells cultured on AFT024, as opposed to human stroma, we determined the numbers of cells with secondary colony-forming ability. Human cells isolated from the bnx bone marrow after 8-12 months engraftment were plated in human-specific colony-forming
Leukemia
Figure 5
Primitive human hematopoietic cell engraftment. Human CD45 
CD38
− cells in the bnx bone marrow were determined by FACS, as cells that bound the HLE-1 (anti-human CD45) antibody from BD, lacked reactivity with HPCA2 (anti-CD34), and lacked reactivity with the Leu 17 (anti-human CD38) antibody from BD. assays as described. 19, 24 From 10 mice transplanted with cells cultured on AFT024 for 2-3 weeks prior to transplantation, an average of 15.4 ± 3.5 human-specific CFU were detected, using previously described methods. 19, 25, 30 From a group of 11 mice transplanted with cells cultured on human stroma for 2-3 weeks prior to transplantation, an average of 5.5 ± 2.3 human-specific CFU were detected, a significantly lower value (P Ͻ 0.05). These data confirm that a higher number of functionally primitive human hematopoietic cells were engrafted in the mice that received cells maintained ex vivo on AFT024 stroma, as opposed to human stroma.
Production of progeny from CD34
+ CD38
− cells in bnx mice
Overall marrow cellularity was no different between mice transplanted with cells from AFT024 cultures and those transplanted with cells from HS cultures. An average of 4.02 × 10 7 ± 3200 total nucleated bone marrow cells were recovered from the four long bones harvested from the bnx mice transplanted with human cells cultured on AFT024 stroma. An average of 3.96 × 10 7 ± 5300 total nucleated bone marrow cells were recovered from the four long bones of the bnx mice transplanted with human cells cultured on human stroma (P Ͻ 0.05). Using the human CD45
+ cell frequency to assess the overall numbers of human hematopoietic progeny in each mouse, it can be calculated that a mean of 5.6 × 10 6 human cells were present in the femur and tibia of mice transplanted with progenitors cultured on AFT024 stroma (at both time points) and 2.1 × 10 6 human cells in mice transplanted with progenitors cultured on HS (P Ͻ 0.05). Given that 2000 CD34 +
CD38
− cells were used to initiate each culture, this represents over a 1000× expansion of cells during a combination of in vitro and in vivo differentiation. While an impressive expansion, this number greatly underestimates the actual number of human cells that was achieved, since not all of the transplanted cells home specifically to the femurs and tibia, but also to other marrow spaces that were not collected in the current studies. Also, it has been reported that only 1% of transplanted human stem/progenitor cells successfully home to the bone marrow at all in murine xenograft models.
31,32
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The minimal human cell numbers that we have calculated here, however, give further proof that cells with expansion, homing, and reconstitution potential were better maintained on AFT024 than on human stroma.
Discussion
In the current studies, we compared ex vivo maintenance of human CD34
− cells isolated from umbilical cord blood, for 2 and 3 weeks on the immortalized murine fetal liver stromal cell line, AFT024, vs primary stromal monolayers derived from post-natal human bone marrow. To assess the capacity for homing, long-term engraftment, and generation of multilineage progeny after the 2-or 3-week culture period, we transplanted the cultured cells into immune-deficient beige/nude/xid mice. We determined that AFT024 stroma supports maintenance of human hematopoietic stem/progenitor cells that are capable of multilineage engraftment at levels superior to those obtained from culture on human stroma. All human hematopoietic lineages examined, T lymphoid, B lymphoid, and myeloid, were detected at higher levels in long-term engrafted mice transplanted with human cells cultured on AFT024, as opposed to human stroma. Human hematopoietic cells with a primitive phenotype, CD45
− and CD45
, were also recovered in significantly higher numbers from the mice that had been transplanted with AFT024-pre-cultured cells, as discussed further below.
Moore et al 1 previously determined that the AFT024 cell line maintains long-term repopulating murine stem cells for up to 7 weeks in vitro. In those studies, the AFT024 line was compared to other cell lines cloned from the same fetal liver source, and was found to be superior at maintaining the engrafting murine stem cells through the in vitro culture period. These data indicate that there are particular stromal cells, which may be located in specific niches, that have a higher capacity than their neighboring stromal cells to maintain hematopoietic stem cells in an undifferentiated state. Moore et al have determined that the AFT024 cell line, but not other cell lines cloned from the same source, and analyzed in comparison, produces the cell surface glycoprotein delta-like (dlk)/preadipocyte factor 1. 33 The dlk protein contains epidermal growth factor-like repeats that are related in sequence to those in the notch/delta family of proteins, and is involved in cell fate decisions. [33] [34] [35] We hypothesize that the dlk protein may also play a role in inhibiting the terminal differentiation of HSC in the AFT024 co-culture system. However, it is likely that one protein alone will not regulate the self-renewal of stem cells, and that a network of regulatory molecules will mediate this function. As we have demonstrated in the current studies, if indeed these regulatory molecules are represented in the AFT024/human stem cell culture system, they appear to have a cross-species function and therefore must be highly conserved.
The population of human hematopoietic cells that has high expression of CD34, but very low expression of the differentiation antigen CD38, is one of the most primitive and quiescent stem/progenitor cell populations that has been identified to date. 14, 24, 36, 37 We have previously demonstrated that the AFT024 stromal cell line supports ex vivo maintenance of the extended long-term culture initiating cell (e-LTCIC) population within human CD34
− cells from human bone marrow and cord blood, at levels superior to human stroma. 2 In agreement with our results, Verfaillie's group reported that the Leukemia AFT024 cell line maintains primitive human hematopoietic cells in culture, through novel 'non-contact' systems, as well as through direct contact. [3] [4] [5] [6] [7] [8] In our previous and current studies, the human progenitor cells were in direct contact with the AFT024 or human stromal monolayers in each experiment. We have now extended those results to demonstrate that the engraftment potential of cultured human stem/progenitor cells is also maintained to better levels following culture on AFT024, as compared to human stroma.
Punzel et al 3 have reported that the number of long-term culture-initiating cells (LTCIC) that can be measured in freshly sorted human CD34
+ cells is dependent upon the type of stromal feeder used. In their studies, the AFT024 stromal line maintained the highest numbers of LTCIC. We agree with the finding of assay-dependent variability, and would extend this theory to propose that the number of human engrafting cells can also be dependent on the type of recipient, immunedeficient mouse host that is used. The commonly used NOD/SCID mouse, for instance, has a relatively short lifespan (6 months average, due to the emv-30 provirus, which causes a lethal thymoma 22 ). In the NOD/SCID mouse, B lymphocytes are the primary lineage that is generated from the transplanted cells. We chose to use the beige nude xid (bnx) mouse in the current studies, because it has a longer lifespan, which allowed the long-term engraftment studies necessary for the work that we have reported, and because we are able to obtain human myeloid cells and progenitors, as well as B and T lymphocytes at levels that allow statistical evaluation of the data. In the current studies, the numbers of engrafting human B lymphoid progenitors that were maintained ex vivo on both types of stroma, AFT024 and human, dropped significantly by 3 weeks of culture. Barker and Verfaillie 6 reported that human hematopoietic progenitors could differentiate to relatively mature B cells in 3 weeks time, when cultured on AFT024. Although their cytokines and culture additions were quite different from those used in our studies, and were deliberately chosen to promote B cell differentiation to create a better in vitro model of early B lymphopoiesis, our data agree with that which they had observed. By 3 weeks in culture, there were relatively few long-term engrafting human B lymphoid progenitors left in the AFT024 cultures, as opposed to the numbers that were obtained when the 2-week AFT024 cultures were transplanted (Figure 4) . The majority of the B cell precursors may, therefore, have entered a state of terminal differentiation between weeks 2 and 3 of culture.
We have previously reported that the numbers and generative capacity of B lymphoid progenitors, measured in the bnx/hu xenograft system, are significantly higher in human umbilical cord blood than in adult or pediatric bone marrow. 27 In the current studies, we estimated that in the 2000 CD34
− cells isolated from umbilical cord blood and seeded into the in vitro cultures, there should have been an average of 60 human hematopoietic progenitors that had the capacity to generate B lymphoid cells, based on calculations that we have previously reported. 27, 38 Even if a proportion of the cells had differentiated to maturity during the duration of the culture, a proportion of the cells had remained primitive enough to sustain B lymphopoiesis in the bnx mice following transplantation (Figure 4 ). In contrast, we have reported that 2000 CD34
− cells from adult or pediatric bone marrow contain an average of only one cell with B lymphopoietic capacity. 27, 38 If that single cell had differentiated to maturity during short-or long-term culture, then there would be no chance of producing human B cells in the mouse that had been transplanted with the contents of that culture. Differ-ences in the relative numbers of cells with B lymphopoietic capacity in the different tissues at least partially explain why we did not observe B cell development in bnx mice from cultured cells isolated from human bone marrow in prior studies, but we did observe B cell development in mice transplanted with cultured cord blood progenitors in the current studies.
In contrast to the loss of B cell generative capacity between 2 and 3 weeks in culture, in the current studies there was no significant reduction in the numbers of progenitors that retained the capacity to generate myeloid or T lymphoid cells. These data could indicate that the T lymphoid and myeloid lineages are derived from a different, less culture-sensitive progenitor than are the B cells. An alternate explanation could be that the culture conditions that we had used in the current studies had pushed a common lymphoid progenitor in the cultures toward development of T, rather than B lymphoid progeny between the 2 and 3 week time points. The generation of human T lymphocytes in bnx mice is interesting because the mice are athymic. Therefore, the human hematopoietic stem/progenitor cell differentiation into mature T cells occurs through extrathymic development. We previously determined that the extrathymically derived human T cells shared common stem cell origins with human myeloid cells recovered from the mice, through clonal integration marking and tracking at the single cell/clone level. 25 Thus, individual human hematopoietic stem cells engrafted in the mice generated myeloid, as well as T lymphoid progeny. We have recently reported that the human T lymphocytes that develop through extrathymic mechanisms are hyporesponsive to anti-CD3 and anti-CD28 or PHA stimuli when recovered from the bnx bone marrow. 18 However, when the human T cells had developed in mice that had systemic human IL-7 production, the responsiveness to in vitro stimuli was restored to levels close to what could be obtained from human peripheral blood T lymphocytes, which had developed with the benefits of thymic selection. 18 In the current studies, we determined that human hematopoietic stem/progenitor cells could retain the capacity to generate T lymphocytes through extrathymic mechanisms to 3 weeks in ex vivo culture. The human stem/progenitor cells that generated the T lymphocytes in the mice were maintained better on AFT024 than on human stroma.
Of even greater interest to us than the superior maintenance of the T cell progenitors on the AFT024 line, was maintenance of the immature, uncommitted human hematopoietic cells to 3 weeks in culture and then up to 1 year in the mice after transplantation. We have recently reported that human cells with secondary reconstitution potential have the phenotype CD45 
/CD38
− cells that were obtained on AFT024 stroma ( Figure 5 ). Human progenitors that lack expression of the differentiation antigen CD38, as well as lacking CD34 have been reported to be primitive hematopoietic cells. 28, 29 The phenotypes of primitive human hematopoietic cells are currently undergoing re-evaluation. It was long believed that all reconstituting human hematopoietic progenitors expressed CD34. However, recently populations of human CD34
− cells have been demonstrated to have hematopoietic potential in vitro, and to have reconstituting capacity in fetal sheep and murine xenograft systems (Refs 9, 23, 28, 29, 39, 40, 42 and Dao, Arevalo and Nolta, manuscript in preparation). Expression of CD34 on primitive cells was hypothesized by Ogawa's group to be activation-dependent. 41 Our data agree with this theory: in long-term engrafted bnx mice, expression of CD34 on human hematopoietic progenitors is downregulated, and is completely absent after 7 months of engraftment. However, a proportion of the human progenitors can upregulate expression of CD34 following secondary transplantation into sublethally irradiated immune-deficient mouse recipients, which serves as an 'activation event' (Refs 23 and 42, Dao, Arevalo and Nolta, manuscript in preparation). Other aspects of the biology of alternative stem cell phenotypes, such as CD34 − cells, are under active investigation in many laboratories. In the current studies, we demonstrated again that human stem/progenitor cells lose expression of CD34 following long-term engraftment (8-12 months). We also demonstrated that cells that were CD45
+ and lacked expression of CD34, CD38, and all other identifiable lineages that were tested (lin − cells), were present at higher levels in the bone marrow of long-term engrafted bnx mice that had been transplanted with human cells cultured on AFT024 stroma, rather than normal human stroma. The number of secondary human colony-forming progenitors that were recovered from the murine marrow was also higher after culture on AFT024, as opposed to human stroma. Therefore, we hypothesize that a factor or combination of factors from this unique cell line can preferentially maintain the primitive human hematopoietic cells during ex vivo culture. The factors responsible for this activity, in addition to the dlk glycoprotein, are currently being identified in Moore's laboratory by cloning and expression studies. 33 A large number of novel proteins have been identified that are produced by AFT024, but not by a related stromal cell line that does not support the maintenance of primitive cells. The biology of the novel factors, which are both secreted and retained at the cell surface, is currently being characterized using in vitro and in vivo systems.
